Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 5/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016775 | 1.00 | CACNA1G (0.83) | CACNA1GKCNH2MAPTKMT2AMEN1 | |
| SCHEMBL2016769 | 1.00 | CACNA1G (0.83) | CACNA1GKCNH2MAPTKMT2AMEN1 | |
| SCHEMBL2016628 | 0.90 | KCNH2 (0.88) | CACNA1GKCNH2MAPTKMT2AMEN1 | |
| SCHEMBL2016631 | 0.90 | KCNH2 (0.88) | CACNA1GKCNH2MAPTKMT2AMEN1 | |
| SCHEMBL2016634 | 0.90 | KCNH2 (0.88) | CACNA1GKCNH2MAPTKMT2AMEN1 | |
| SCHEMBL2019901 | 0.87 | MEN1 (0.78) | CACNA1GKCNH2MAPTKMT2AMEN1 | |
| SCHEMBL2019903 | 0.87 | MEN1 (0.78) | CACNA1GKCNH2MAPTKMT2AMEN1 | |
| SCHEMBL2019905 | 0.87 | MEN1 (0.78) | CACNA1GKCNH2MAPTKMT2AMEN1 | |
| SCHEMBL2017996 | 0.87 | MAPT (0.74) | CACNA1GKCNH2MAPTKMT2AMAPK1 | |
| SCHEMBL2017993 | 0.87 | MAPT (0.74) | CACNA1GKCNH2MAPTKMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170334-B1 | NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION | UNIV EMORY (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-2170334-B1 | NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION | UNIV EMORY (US) | 2021-03-17 | — | — | EP | disclosed |
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | CACNA1G 241/4885KCNH2 137/4885MAPT 2477/4885 |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | GRIN2A, GRIN2B, GRIN1 | CACNA1G 161/4885KCNH2 469/4885MAPT 704/4885 |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | CACNA1G 251/4885KCNH2 135/4885MAPT 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.